Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

Bolger, GT, Licollari, A, Tan, A, Greil, R, Pleyer, L, Vcelar, B, Majeed, M, Sordillo, P. Anticancer Res. 2018, 38(1): 12-130.

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer, F, Thaler, J, Piringer, G, Hackl, H, Pleyer, L, Hufnagl, C, Weiss, L, Greil, R. BMC Cancer. 2018, 18(1): 11.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt, T, Magnes, T, Hufnagl, C, Thorner, AR, Ducar, M, Neureiter, D, Tränkenschuh, W, Klieser, E, Gaggl, A, Rösch, S, Rasp, G, Hartmann, TN, Pleyer, L, Rinnerthaler, G, Weiss, L, Greil, R, Egle, A. Eur J Cancer. 2018, 93:69-78.

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

Cavo, M, Terpos, E, Bargay, J, Einsele, H, Cavet, J, Greil, R, de Wit, E. Expert Rev Hematol. 2018, 11(3):219-237.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer, F, Weiss, L, Faber, V, Neureiter, D, Egle, A, Geissler, K, Voskova, D, Zebisch, A, Burgstaller, S, Pichler, A, Stauder, R, Sperr, W, Lang, A, Pfeilstöcker, M, Machherndl-Spandl, S, Stampfl, M, Greil, R, Pleyer, L. Wien Klin Wochenschr. 2018.

A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.

Piringer, G, Fridrik, M, Fridrik, A, Leiherer, A, Zabernigg, A, Greil, R, Eisterer, W, Tschmelitsch, J, Lang, A, Frantal, S, Burgstaller, S, Gnant, M, Thaler, J. Support Care Cancer. 2018, 26(4):1345-1352.

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1.

Burgstaller, S, Stauder, R, Kuehr, T, Lang, A, Machherndl-Spandl, S, Mayrbaeurl, B, Noesslinger, T, Petzer, A, Valent, P, Greil, R, Thaler, J. Leuk Lymphoma. 2018, 59(5):1121-1126.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes, J, Pleyer, L, Thépot, S, Almeida, AM, Maurillo, L, Martínez-Robles, V, Stauder, R, Itzykson, R, Pinto, R, Venditti, A, Bargay, J, Burgstaller, S, Martínez, MP, Seegers, V, Cortesão, E, Foncillas, MÁ, Gardin, C, Montesinos, P, Musto, P, Fenaux, P, Greil, R, Sanz, MA, Ramos, F, Leuk Lymphoma. 2018, 59(5):1113-1120.

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C. Eur J Haematol. 2020; 104(3):251-258.

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

Wagner, SM; Melchardt, T; Greil, R. DRUG TODAY. 2020; 56(3): 195-202.